非小細胞肺癌市場：按類型、治療方法、最終用戶和地區分類

Non-Small Cell Lung Cancer Market, By Type, By Treatment, By End User, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年非小細胞肺癌市場規模估計為314.1億美元，預計2033年將達到604.4億美元。預計2026年至2033年，該市場將以9.8%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	314.1億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	9.80%	2033年市場規模預測：	604.4億美元

非小細胞肺癌（NSCLC）是最常見的肺癌類型，約佔所有肺癌病例的85%。它是全球癌症死亡的主要原因之一。全球非小細胞肺癌市場成長的促進因素包括吸煙習慣的增加和環境污染的加劇、先進治療方法研發活動的活性化以及對標靶治療和個性化醫療需求的成長。然而，高昂的治療費用正在阻礙市場成長。

市場動態

全球非小細胞肺癌市場正在成長，其成長動力主要來自吸菸率上升、環境污染加劇以及已開發國家和開發中國家人口老化。根據世界衛生組織統計，全球每年新增肺癌病例約180萬例，其中絕大多數為非小細胞肺癌。標靶治療和癌症治療方法的進步為市場相關人員創造了商機。然而，標靶治療的認知不足阻礙了市場成長。此外，藥物臨床試驗失敗的風險也對研發活動產生負面影響。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球非小細胞肺癌市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使企業負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球非小細胞肺癌市場報告」旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過對全球非小細胞肺癌市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- F. Hoffmann-La Roche Ltd.
- Honeywell International Inc.
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG

第9章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第10章

參考
調查方法

簡介目錄

Product Code: CMI241

Non-Small Cell Lung Cancer Market is estimated to be valued at USD 31.41 Bn in 2026 and is expected to reach USD 60.44 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 31.41 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.80%	2033 Value Projection:	USD 60.44 Bn

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.

Market Dynamics

Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.

Market Segmentation

Type Insights (Revenue, USD Bn, 2021 - 2033)
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors
Treatment Insights (Revenue, USD Bn, 2021 - 2033)
Chemotherapy
Targeted Therapy
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
Immunotherapy
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
Others
End User Insights (Revenue, USD Bn, 2021 - 2033)
Hospitals
Homecare
Specialty Clinics
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
F. Hoffmann-La Roche Ltd.
Honeywell International Inc.
AstraZeneca PLC
Merck & Co., Inc.
Pfizer Inc.
Bristol-Myers Squibb Company
Novartis AG
Eli Lilly and Company
Boehringer Ingelheim International GmbH
Celgene Corporation
Amgen Inc.
Johnson & Johnson
Gilead Sciences, Inc.
AbbVie Inc.
Astellas Pharma Inc.
Takeda Pharmaceutical Company Limited
Sanofi
Teva Pharmaceutical Industries Ltd.
Bayer AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Non-Small Cell Lung Cancer Market, By Type, 2021 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adenocarcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Squamous Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Large Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Large Cell Neuroendocrine Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Non-Small Cell Lung Cancer Market, By Treatment, 2021 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  - Bevacizumab (Avastin)
  - Necitumumab (Portrazza)
  - Ramucirumab (Cyramza)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  - Nivolumab (Opdivo)
  - Atezolizumab (Tecentriq)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Non-Small Cell Lung Cancer Market, By End User, 2021 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospitals
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Home Care
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Non-Small Cell Lung Cancer Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche Ltd.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Honeywell International Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca PLC
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Celgene Corporation
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Johnson & Johnson
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Gilead Sciences, Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Astellas Pharma Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sanofi
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies